(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/148511 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/24* (2006.01)
A61K 9/127 (2006.01) *A61K 38/00* (2006.01)
A61K 9/51 (2006.01) *A61K 39/00* (2006.01)
A61K 47/14 (2017.01)

(21) International Application Number:
PCT/EP2021/051290

(22) International Filing Date:
21 January 2021 (21.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20152938.5	21 January 2020 (21.01.2020)	EP
20152995.5	21 January 2020 (21.01.2020)	EP
20179434.4	11 June 2020 (11.06.2020)	EP

(71) Applicant: **ETHERNA IMMUNOTHERAPIES NV** [BE/BE]; Galileilaan 19, 2845 Niel (BE).

(72) Inventors: **DE KOKER, Stefaan**; Galileilaan 19, 2845 Niel (BE). **BEVERS, Sanne**; Galileilaan 19, 2845 Niel (BE). **SCHIFFELERS, Raymond, Michel**; UMC Utrecht Holding B.V., Yalelaan 40, 3584CM Utrecht (NL). **KOOIJMANS, Sander, Alexander, Antonius**; UMC Utrecht Holding B.V., Yalelaan 40, 3584CM Utrecht (NL).


(74) Agent: **ARNOLD & SIEDSMA BV**; Bezuidenhoutseweg 57, 2594 AC The Hague (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: LIPID NANOPARTICLES

Fig. 1



(57) Abstract: The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionizable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in comprising less than about 1 mol% of a C18-PEG2000 lipid. The present invention provides use of the LNP's for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.

WO 2021/148511 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*